Enters 2020 with a Strong Balance Sheet and an Advancing Clinical Pipeline Conference Call Begins at 11:00 a.m. Eastern Time on Thursday March 26, 2020 LAWRENCEVILLE, N.J. , March 25, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug development company, today announced

Approval Adds 10 Years of Market Exclusivity Following Marketing Authorization in Europe LAWRENCEVILLE, N.J. , March 23, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced the European Medicines Agency (EMA) Committee for Orphan

  Company to Provide Update on its Phase III OPTIMA Study in Primary Liver Cancer  and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J. , March 19, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss

  R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only Company to Proceed with Phase II Portion of the OVATION 2 Study After All Phase I Patients Have Completed Their Full Treatment Regimen (up to

LAWRENCEVILLE, N.J. , March 03, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announces that Michael H. Tardugno , the company’s chairman, president and chief executive officer, issued the following letter to stockholders.

LAWRENCEVILLE, NJ , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 4,571,428 shares of the Company’s common stock, par

  Phase 2 Portion Will Continue After Patients Have Completed Their Full Treatment Regimen of up to 17 doses of GEN-1 plus Standard Chemotherapy LAWRENCEVILLE, N.J. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) today announced that the independent Data Safety Monitoring

Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020 LAWRENCEVILLE, N.J. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug-development company, announces that Prof.

Memorandum of Understanding completed with Chinese government officials in the Yuhang district of Hangzhou , China’s biotech hub, to develop and commercialize innovative cancer therapies starting with ThermoDox ® . Agreement includes numerous financial and non-financial incentives including grants

  Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share Assures Funding Through Major Company Events; Company Provides Guidance on the Timing of Upcoming Development Milestones for the Phase III OPTIMA Study and the Phase I/II OVATION 2 Study LAWRENCEVILLE,